Welcome Regor to Bridge 12 Community ??

It is an honor for us to introduce Regor as a new member of our bridge 12 community. Regor is a pioneering clinical stage biotech company, headquartered in Shanghai, China and Boston, USA. It was founded in 2018 by a team of accomplished scientists with a proven track record in drug discovery and executive leadership in top global biopharmaceutical companies.

Regor’s current therapeutic areas of interest include oncology, metabolic diseases and autoimmune diseases. By leveraging industry-leading core strength in CARD (Computer Accelerated Rational Discovery), Regor is committed to creating a highly efficient ecosystem for accelerated discovery of innovative therapeutic agents with differentiated therapeutic values for patients around the world. With a strong focus on excellence in pharmaceutical research and global competitiveness, the company aspires to build a world-class innovation engine that promotes a winning culture of scientific excellence, strong teamwork driven by results and delivery with shared accountability and successes.

In Feburary 2021, Regor completed 90 million series B financing.?

In December 2021, Regor Therapeutics announced authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans for RGT-419B.

In March 2022, Regor entered into collaboration with NVIDIA corporation to integrate high performance computing technology into Regor's proprietary Artificial Intelligence innovation platform - rCARDTM - to accelerate the discovery and development of innovative drugs.

The Company has embarked upon three therapeutic areas, Metabolic diseases, Oncology, and Immunology.

Oncology

Regor’s research and development efforts aim to generate effective therapeutics solutions based on profound understanding of molecular targets and pathways in immune-oncology and tumor proliferation and development. It seeks deep insights on which tumor pathogenesis, development and interaction with the immune system is based, and thus innovate pan-tumor treatment modality with FIC/BIC new molecular entities to bring new hope to patients worldwide.

Metabolic Disorders

Metabolic disorders including diabetes, obesity and NASH caused a significant healthcare burden globally and deeply impacted the lives of hundreds of millions of world population. Regor’s drug discovery and development in this therapeutic area envisions a novel solution with effective metabolic profile management that significantly improves patients’ quality of life and provide patients with better experience of drug administration so that an effective long-term disease management can be realized.

Immunology

Auto-immune disease patients suffer from disease attack and progress with a long course of journey and thus quality of life is severely impacted. Patients are faced with tremendous unmet medical needs with current disease modifying medications. Regor’s research and development platform is developing next generation anti-autoimmune medication that seek breakthrough in mode of actions and fulfill more effective disease management and control.

About Bridge 12

Operated by CUBIC and housed at CIC, Bridge12 is a community that provides a strong network, mentorship programs, and consulting services to unlock the path to China for promising US companies. Bridge12 holds Afternoon Tea Seminars every month, sharing valuable opinions and information on legal, manufacturing, and biological field, helping US companies learn about China’s market.

About Cubic?

CUBIC is the ultimate platform for emerging and growing companies seeking to expand their market to China or establish a business presence in China. Our experienced professional teams expertly facilitate cross-border business collaboration in the market acquisition, in-China entity establishment, and funding acquisition. We connect our clients to suppliers, vendors, strategic partners, and potential buyers through our partner network in China. Our services aim to meet the needs of companies at every stage of growth to accelerate their path to global success.

?

References:

BioSpace. (2021, February 19). Regor Therapeutics announces completion of $90 Million series B financing. BioSpace. Retrieved April 7, 2022, from https://www.biospace.com/article/releases/regor-therapeutics-announces-completion-of-90-million-series-b-financing/

Investank. (2021, December 28). Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology. Regor Therapeutics宣布美国FDA授权进行Regor的首次人体临床试验，使用下一代靶向抑制剂RGT-419B用于肿瘤学. Retrieved April 7, 2022, from https://www.investank.com/news/detail/828376

Regor. (2022). Regor Therapeutics Group. Retrieved April 7, 2022, from https://www.regor.com/?

?

?

?